Literature DB >> 6441630

A model for malignancy-associated humoral hypercalcemia.

E C Abramson, L J Kukla, D H Shevrin, T E Lad, W P McGuire, S C Kukreja.   

Abstract

Tumor tissue from a patient with squamous cell carcinoma of the lung and hypercalcemia has been serially implanted into athymic mice. Tumor-bearing mice develop cachexia, hypercalcemia without bone metastases, hypophosphatemia, increased urinary cyclic adenosine monophosphate (cAMP) to creatinine ratio, and undetectable human immunoreactive parathyroid hormone levels. Radiographs of spines in the tumor-bearing mice demonstrate demineralization, suggesting skeletal resorption as the source of the hypercalcemia. Within 4-8 hours following tumor removal, hypercalcemia is reversed, suggesting that a relatively short-acting humoral substance is responsible for the hypercalcemia. The animals gain weight and become essentially normal within 4 days following tumor removal. The studies demonstrate that this animal model is similar in many aspects to human malignancy-associated humoral hypercalcemia (MAHH) and can provide a useful tool for further investigation of the pathogenesis and treatment of this syndrome.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6441630     DOI: 10.1007/bf02405367

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  19 in total

1.  Prostaglandin-mediated hypercalcemia in the VX2 carcinoma-bearing rabbit.

Authors:  H W Seyberth; W C Hubbard; O Oelz; B J Sweetman; J T Watson; J A Oates
Journal:  Prostaglandins       Date:  1977-08

2.  Prostaglandin E and hypercalcemia in breast carcinoma: only a tumor marker? A need for perspective.

Authors:  J F Caro; A Besarab; J T Flynn
Journal:  Am J Med       Date:  1979-02       Impact factor: 4.965

3.  Urinary and nephrogenous adenosine 3',5'-monophosphate in the hypercalcemia of malignancy.

Authors:  R K Rude; C F Sharp; R S Fredericks; S B Oldham; N Elbaum; J Link; L Irwin; F R Singer
Journal:  J Clin Endocrinol Metab       Date:  1981-04       Impact factor: 5.958

4.  Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups.

Authors:  A F Stewart; R Horst; L J Deftos; E C Cadman; R Lang; A E Broadus
Journal:  N Engl J Med       Date:  1980-12-11       Impact factor: 91.245

5.  Prostaglandins, calcium metabolism and cancer.

Authors:  A H Tashjian; E F Voelkel; P Goldhaber; L Levine
Journal:  Fed Proc       Date:  1974-01

6.  The hypercalcaemic syndrome in rats bearing the Walker carcinosarcoma 256.

Authors:  H Minne; F Raue; S Bellwinkel; R Ziegler
Journal:  Acta Endocrinol (Copenh)       Date:  1975-03

7.  Nephrogenous cyclic adenosine monophosphate levels in normocalcemic cancer patients: its significance.

Authors:  E C Abramson; S C Kukreja; T E Lad; W P Shemerdiak; P A York
Journal:  Horm Metab Res       Date:  1984-04       Impact factor: 2.936

8.  Human renal carcinoma cells produce hypercalcemia in the nude mouse and a novel protein recognized by parathyroid hormone receptors.

Authors:  G J Strewler; R D Williams; R A Nissenson
Journal:  J Clin Invest       Date:  1983-03       Impact factor: 14.808

9.  Relation of osteoclast activating factor production to extent of bone disease in multiple myeloma.

Authors:  B G Durie; S E Salmon; G R Mundy
Journal:  Br J Haematol       Date:  1981-01       Impact factor: 6.998

10.  Heterotransplantation of human cancers into nude mice: a model system for human cancer chemotherapy.

Authors:  B C Giovanella; J S Stehlin; L J Williams; S S Lee; R C Shepard
Journal:  Cancer       Date:  1978-11       Impact factor: 6.860

View more
  3 in total

1.  Antibodies to parathyroid hormone-related protein lower serum calcium in athymic mouse models of malignancy-associated hypercalcemia due to human tumors.

Authors:  S C Kukreja; D H Shevrin; S A Wimbiscus; P R Ebeling; J A Danks; C P Rodda; W I Wood; T J Martin
Journal:  J Clin Invest       Date:  1988-11       Impact factor: 14.808

2.  A hypercalcemic nude rat model that completely mimics human syndrome of humoral hypercalcemia of malignancy.

Authors:  K Ikeda; T Matsumoto; S Fukumoto; K Kurokawa; Y Ueyama; K Fujishige; N Tamaoki; T Saito; K Ohtake; E Ogata
Journal:  Calcif Tissue Int       Date:  1988-08       Impact factor: 4.333

Review 3.  Nutritional Interventions in Cancer Cachexia: Evidence and Perspectives From Experimental Models.

Authors:  Wouter R P H van de Worp; Annemie M W J Schols; Jan Theys; Ardy van Helvoort; Ramon C J Langen
Journal:  Front Nutr       Date:  2020-12-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.